FRM
IOVA icon

Fox Run Management’s Iovance Biotherapeutics IOVA Stock Holding History

Fox Run Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,015
Closed -$80.3K – 945
2024
Q2 		$80.3K Buy
+10,015
New +$107K 0.02% 731
2024
Q1 		– Sell
-22,712
Closed -$185K – 924
2023
Q4 		$185K Buy
22,712
+6,633
+41% +$34.7K 0.05% 641
2023
Q3 		$73.2K Buy
+16,079
New +$105K 0.02% 646
2022
Q4 		– Sell
-17,419
Closed -$167K – 755
2022
Q3 		$167K Buy
+17,419
New +$201K 0.07% 506
2022
Q2 		– Sell
-17,380
Closed -$289K – 635
2022
Q1 		$289K Buy
17,380
+4,918
+39% +$76.1K 0.16% 285
2021
Q4 		$238K Buy
12,462
+427
+4% +$9.4K 0.14% 307
2021
Q3 		$297K Buy
+12,035
New +$284K 0.19% 233
2020
Q3 		– Sell
-7,670
Closed -$211K – 247
2020
Q2 		$211K Buy
+7,670
New +$252K 0.28% 199
2020
Q1 		– Sell
-11,878
Closed -$329K – 244
2019
Q4 		$329K Buy
+11,878
New +$270K 0.26% 151
2018
Q2 		– Sell
-13,713
Closed -$232K – 790
2018
Q1 		$232K Buy
+13,713
New +$208K 0.06% 582

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fox Run Management's IOVA Position: Q3 2024 in Review

Fox Run Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 10,015 shares — an estimated $80.3K sold.

Fox Run Management first reported a position in IOVA in Q1 2018 and held it in 10 quarters. The position peaked at $329K in Q4 2019. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Fox Run Management reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Fox Run Management sold 10,015 Iovance Biotherapeutics shares in Q3 2024, an estimated $80.3K.
  • Fox Run Management first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 10 quarters.
  • Fox Run Management's Iovance Biotherapeutics position peaked at $329K in Q4 2019.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Fox Run Management's 13F filing for Q3 2024, filed 12 Nov 2024.